A Phase I–II trial of intravenously administered AUY922 is currently open, with the Phase I portion of the trial recruiting patients with several types of cancer, whilst the Phase II portion is limited to patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer [76]. This evidence concerns the gene ERBB2 and cancer.